Study identifier:D0810C00042
ClinicalTrials.gov identifier:NCT01078662
EudraCT identifier:2010-022278-15
CTIS identifier:N/A
A Phase II, Open label, Non randomised, Non comparative, Multicentre study to assess the efficacy and safety of olaparib given orally twice daily in patients with advanced cancers who have a confirmed genetic BRCA 1 and/or BRCA2 mutation
ovarian
Phase 2
No
olaparib
All
298
Interventional
18 Years - 130 Years
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
Location
Location
Melbourne, Australia, 3000
Location
Randwick, Australia, 2031
Location
Köln, Germany, 50931
Location
Madrid, Spain, 08035
Location
Petah Tikva, Israel, 49100
Location
Jerusalem, Israel, 91031
Location
Haifa, Israel, 35152
Location
Lund, Sweden, 221 85
Arms | Assigned Interventions |
---|---|
Experimental: 1 Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator. Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions. | Drug: olaparib Tablets Oral BID Other Name: Lynparza |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.